Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations
We estimated the progression-free time at each 0.5 unit Clinical Dementia Rating Sum of Boxes increment in dominantly inherited Alzheimer's disease (AD) and sporadic AD populations. We proposed using progression-free time to estimate treatment effects in open-label extension or single-arm studies. If further validated, progression-free time could serve as a benchmark for assessing clinical progression and treatment effects.
Authors
- Randall John Bateman (ORCID: https://orcid.org/0000-0002-7729-1702)
- Sarah M. Hartz (ORCID: https://orcid.org/0000-0002-5429-3799)
- Lon S. Schneider (ORCID: https://orcid.org/0000-0002-4636-6150)
- Eric McDade (ORCID: https://orcid.org/0000-0002-6764-3866)
- Chengjie Xiong
- Christopher M. Morris (ORCID: https://orcid.org/0000-0002-3749-0993)
- Yan Li (ORCID: https://orcid.org/0000-0002-5587-2784)
- Guoqiao Wang (ORCID: https://orcid.org/0000-0002-6808-8737)
Institutions
- University of Southern California (US)
- Washington University in St. Louis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/alz.70643
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Eli Lilly and Company
- Biogen
- Della Martin Foundation
- Eisai
- Novo Nordisk
- H. Lundbeck A/S
- Ministry of Science and ICT, South Korea
- National Institutes of Health
- Genentech
- University of California, San Diego
- GW Research
- National Institute on Aging